Abbreviations: P450, cytochrome P450; NADPH, nicotinamide adenine dinucleotide phosphate, reduced; f m , fraction metabolized.
Introduction
CYP4F12 is a member of the cytochrome P450 (P450) family of drug metabolizing enzymes that is primarily expressed in the liver, small intestine, colon, kidney and heart (Bylund et al., 2001; Guengerich, 2005; Hashizume et al., 2001) . Currently, there is limited information available on the relative protein expression levels of CYP4F12, however initial analyses would suggest that it is a widely expressed but relatively minor P450 isoform (Stark et al., 2004) .
Sequence alignment of the amino acid sequence of CYP4F12 indicates it is approximately 78 -83% homologous with the other members of the CYP4F family. To date, seven allelic variants of the enzyme have been identified, with two of the seven exhibiting altered kinetics (Bylund et al., 2001; Cauffiez et al., 2004) . CYP4F12 expression has been shown to be inducible through activation of the p53 pathway, a sequence-specific transcription factor known to regulate the expression of multiple P450 isoforms, and also exhibits an increased binding to the pregnane-X receptor in the presence of rifampicin (Goldstein et al., 2013; Hariparsad et al., 2009 ).
The P450 family of drug metabolizing enzymes is capable of catalyzing the metabolism of substrates with a wide array of structural and physical chemical attributes (Johnson and Stout, 2005; Lewis et al., 1999; Lewis et al., 1998) . CYP4F12 exhibits similar pharmacophore attributes to other CYP4 isoforms as well as P450 BM3, with known endogenous substrates including arachidonic acid, leukotriene B4 and prostaglandins (Bylund et al., 2001; Kikuta et al., D M D # 5 9 6 2 6 5 specific homeostatic isoforms such as CYP26A1 (Foti et al., 2011) .
The objective of the work presented here was to characterize the active site properties of CYP4F12 that result in a decreased catalytic promiscuity through detailed kinetic analyses and molecular modeling. A thorough structural assessment was conducted in order to determine which physicochemical properties result in an increased inhibitory potency for CYP4F12.
Metabolite identification assays were carried out to identify the sites of metabolism for astemizole with CYP4F12 as compared to CYP3A4, a P450 isoform with a well-documented ability to catalyze a wide range of substrates. Using kinetic isotope experiments, the ability of CYP4F12 to allow for metabolic switching for a given substrate in its active site was probed.
Finally, a homology model of CYP4F12 was designed and compared to crystal structure data of CYP3A4 in an attempt to rationalize the current in vitro findings and ultimately to characterize the active site properties of CYP4F12. Following a 5 minute pre-incubation period at 37 ºC, the incubations were initiated with 1 mM NADPH (final concentration) and allowed to proceed for 20 minutes. Metabolite identification incubations were extracted into 3 volumes of ethyl acetate and vortexed for 5 minutes. The organic layer was collected and evaporated to dryness under a gentle stream of N 2 . Samples were reconstituted in water:acetonitrile (95:5) and placed into vials for LC-MS/MS analysis.
Kinetic Isotope Effects on Intrinsic Clearance and Metabolite Formation. O-demethylation
of the methoxyphenyl moiety of astemizole has previously been reported to be a major metabolic pathway for astemizole by CYP4F12 (Matsumoto and Yamazoe, 2001 The Q-Trap mass spectrometer was coupled to a liquid chromatography system consisting of two LC-20AD pumps with an in-line CBM-20A controller and DGU-20A 5 solvent degasser (Shimadzu, Columbia, MD) and to a LEAP CTC HTS PAL autosampler equipped with a dual-solvent self-washing system (CTC Analytics, Carrboro, NC). HPLC separation was achieved using a Gemini C 18 2.0 x 30 mm 5 µm column (Phenomenex, Torrance, CA). Rapid gradient elution (flow rate = 400 µL/min) was carried out using a mobile phase system consisting of (A) 5 mM ammonium formate with 0.1% formic acid and (B) acetonitrile with 0.1% formic acid. HPLC flow was diverted to waste for the first minute to remove any non-volatile
salts. An injection volume of 10 μ L was used for all analytes.
For metabolite identification analyses, chromatographic separation was achieved using a Kinetex C 18 2.1 X 100 mm 2.7 μ m column (Phenomenex, Torrance, CA). Gradient elution (flow rate = 200 µL/min) was carried out using a mobile phase system consisting of (A) water with 0.1% formic acid and (B) acetonitrile:methanol (1:1) with 0.1% formic acid. HPLC flow was diverted to waste for the first two minutes to remove any non-volatile salts. An injection volume of 15 μ L was used for all analyses. Mobile phase B was held at 2.5% for the first 2 minutes, increased linearly from 2.5% to 33% from 2 to 6.5 minutes, from 33% to 45% from 6.5 to 16 minutes, increased to 95% at 17 minutes and held at 95% for 1 minute prior to re-equilibration at 2.5% B for 2 minutes. Metabolites were initially identified using a Q1 scan (100 -800 amu).
Additional analysis was conducting using MRM transitions for astemizole and its metabolites.
The analytes monitored were astemizole ( 
CYP4F12 Homology Modeling.
A three-dimensional homology model of CYP4F12 was developed using Prime (Schrodinger, Portland, OR). The CYP4F12 amino acid sequence was obtained from GenBank (AAQ89336.1) with the crystal structure of P450 BM3 (PDB 1JPZ) serving as the template for the homology model (30% sequence identity). While BLAST searches identified CYP3A4 as another plausible template based on sequence identity and total sequence alignment score, BM3 was chosen as the template as to not bias the subsequent comparison to the CYP3A4 crystal structure. The structural plausibility of the CYP4F12 homology model was determined through evaluation of the Ramachandran plot and through visualization of bond angles and lengths. Local flexibility/rigidity was assessed by visual inspection of helices as compared to loop regions and through secondary structure predictions performed in PSIPRED (University College London, UK) and SSPro (Schrodinger, Portland, OR). The active site of the CYP4F12 homology model was defined using SiteMap (Schrodinger, Portland, OR) and a docking grid generated using a 14 x 14 x 14 Å 3 box that was used to constrain the center of mass of the docked ligand. The astemizole structure was prepared prior to docking using LigPrep 2.0 (Schrodinger, Portland, OR) which converts two-dimensional .mol files to three-dimensional molecular structures with defined stereocenters. Following conversion, the astemizole structure underwent a minimization step using a distance dependent dielectric model and the OPLS_2005 force field. Astemizole was then docked into the homology model of CYP4F12 or the crystal structure of CYP3A4 (PDB 1W0G) using Glide (Schrodinger, Portland, OR) and evaluated by GlideScore and eModel. Induced-fit docking algorithms (Sherman et al., 2006a; Sherman et al., 2006b ) which allow for reduced van der D M D # 5 9 6 2 6 1 3
Waals radii, removal and reorientation of non-rigid protein side chains and a second energy minimization step upon ligand docking were used to dock astemizole into the homology model of CYP4F12 and for two of the three orientations within the active site of the CYP3A4 crystal structure model (O-demethylation and N-dealkylation orientations).
CAVER 3.0.1 (CaverSoft, Brno, Czech Republic) was used to estimate the active site volumes of the CYP4F12 homology model and the CYP3A4 crystal structure as previously described (Chovancova et al., 2012; Petrek et al., 2006; VandenBrink et al., 2012) . Protein structures were prepared in Maestro (Schrodinger, Portland OR) prior to CAVER analysis.
Initial optimization steps included correction for missing hydrogen atoms, removal of water molecules and definition of the formal charge on the heme iron at Fe 3+ . The Maestro script automatically assigned protonation states for all arginine, glutamine and histidine residues.
Following optimization of the hydrogen bonding network, the entire protein structure was subject to a restrained energy minimization after which each protein structure was imported into CAVER. The active site of each enzyme was defined with respect to a water ligand that was positioned axial to the heme prosthetic group. Active site volume estimates were obtained using embedded molecular dynamics trajectory files within CAVER and graphically visualized through PyMOL (Schrodinger, Portland, OR). mL/min/nmol P450 and 60.8 mL/min/nmol P450, respectively (Supplemental Table 1 A homology model was designed for CYP4F12 using P450 BM3 (PDB 1JPZ) as a template and compared to CYP3A4 using crystal structure data (PDB 1W0G). arachidonic acid, 9,11-diazo-prostaglandin H 2 and 9,11-methanoepoxy-prostaglandin H 2 (Bylund et al., 2001) . The enzyme can also metabolize xenobiotics such as astemizole, terfenadine and ebastine (Lee et al., 2010; Parikh et al., 2003) . Though no mechanistic explanation was available at the time, studies to compare the substrate profiles of ten P450
isoforms concluded that while CYP4F12 is susceptible to inhibition by many of the same ligands as other P450 enzymes, the ability of the enzyme to metabolize the same compounds is relatively restricted (Foti et al., 2011) . The objective of this manuscript was to characterize the active site properties of CYP4F12 as a means to rationalize the decreased catalytic promiscuity through kinetic analyses and homology modeling.
Efforts to characterize the inhibitory properties of 53 compounds against CYP4F12 resulted in IC 50 values from 78 nM for amiodarone to > 100 μ M for 13 of the compounds.
Lipophilicity is a well characterized property of P450 ligands that can influence inhibition potency (Lewis and Dickins, 2003; Lewis et al., 2004) . This was true for CYP4F12 as the molecular O-demethylation has been reported to be a metabolic pathway for astemizole by multiple P450s (Hashizume et al., 2002; Lee et al., 2010; Matsumoto and Yamazoe, 2001; Parikh et al., 2003) . Consistent with these results, O-demethylation accounted for over 99% of the metabolites formed by CYP4F12. Trace amounts of 6-hydroxyastemizole, fluorophenyl-OH astemizole and N-desalkylastemizole were also observed suggesting that while it is plausible for astemizole to achieve multiple binding orientations in the active site of CYP4F12, the additional orientations are less catalytically favorable. While O-demethylation was also catalyzed by CYP3A4, it accounted for only 39% of the metabolites formed, with 6-hydroxyastemizole, fluorophenyl-OH and hydroxylation on the methoxyphenyl ring all accounting for significant fractions of the overall metabolism. Unlike CYP4F12, the relative similarity of the f m values for CYP3A4 suggests that conditions exist within the active site of CYP3A4 for astemizole to achieve multiple catalytically favorable orientations.
To further compare the active sites of CYP4F12 and CYP3A4, incubations were performed using d 3 -astemizole. The use of isotope effects to evaluate a ligand's ability to freely reorient within an active site has been described previously (Henne et al., 2001; Iyer et al., 1997) . The basis for these experiments begins with the symmetry of the transition state for the bond-cleaving reaction step (C-H or C-D) and results in an alteration to the rate constant for that step (Kim et al., 2006; Lu et al., 1984; Manchester et al., 1997; Miwa and Lu, 1987; Miwa et al., 1984; Nelson and Trager, 2003; Westheimer, 1961) . When d 3 -astemizole was incubated with recombinant CYP4F12, an isotope effect of 7.1 ((V max /K m ), H / (V max /K m ) ,D ) was observed for the formation of O-desmethylastemizole with an 8.3-fold decrease in the clearance of the substrate.
No alternative metabolites were observed with CYP4F12 suggesting that the active site architecture of CYP4F12 is such that the substrate is unable to rapidly reorient itself. When kinetic isotope effect experiments were conducted with recombinant CYP3A4, an isotope effect D M D # 5 9 6 2 6 1 9
was also observed for the formation of O-desmethylastemizole, however it was reduced to 3.8 ((V max /K m ), H / (V max /K m ) ,D ) with no effect on the clearance of astemizole. Inverse isotope effects were observed for the formation of 6-hydroxyastemizole (0.8), fluorophenyl-OH astemizole (0.47) and methoxyphenyl-OH astemizole (0.45) with CYP3A4. One explanation may be that isotopically sensitive branching to the three hydroxylated metabolites is masking the kinetic isotope effect at the site of O-demethylation and that the lack of an effect on the clearance of astemizole is a combination of the metabolic branching and the relatively low f m value for this metabolic pathway (Atkins and Sligar, 1987; Harada et al., 1984; Jones et al., 1986; Korzekwa et al., 1989; Miwa and Lu, 1987; Nelson and Trager, 2003) . Furthermore, the P450 catalytic cycle is known to include three nonproductive (uncoupling) pathways of which only the formation of water from Compound I results in an NADPH to O 2 ratio of 2:1. The approximate 2-fold increase in the NADPH consumption rate which was observed for CYP4F12 and d 3 -astemizole with no increase in the formation of H 2 O 2 suggests that the enzymatic reaction may be branching to this uncoupling pathway and resulting in the formation of an additional water molecule from Compound I (Atkins and Sligar, 1988; Grinkova et al., 2013) .
Finally, to rationalize the previously discussed results using the active site geometries of CYP4F12 and CYP3A4, a homology model was designed for CYP4F12 and compared to an xray crystal structure model of CYP3A4. Upon docking, only a single orientation was achieved with CYP4F12 while three orientations were obtained with CYP3A4. Binding of astemizole in the CYP4F12 model required an induced-fit docking approach, indicating that the active site of the enzyme is relatively constrained. The majority of the active site residues that were located CYP3A4 active site and was constrained in a long, cylindrical nature. The region of the CYP4F12 active site with the greatest structural divergence from CYP3A4 appeared to be in the region of the F and G helices, where CYP4F12 appears to have a rigid helical motif similar to P450 BM3 as opposed to the more flexible helix-loop-helix motifs of the CYP3A4 F and G helix structures (Ekroos and Sjogren, 2006; Joyce et al., 2004; Ohkura et al., 2009) . The overall mobility of the F / G loop in P450 isoforms has been proposed as a determinant of a P450 to bind diverse ligands and one could argue that rigidity in this region of CYP4F12 contributes to the narrow substrate profile of the enzyme (Poulos, 2003; Scott et al., 2003) . The estimated volume of the active site of CYP4F12 suggests it is similar in size to the larger P450 active sites such as CYP3A4 and CYPC8, though the overall flexibility and volume changes upon substrate binding remain to be determined.
Consistent with its metabolic profile, multiple binding orientations were obtained with the CYP3A4 model. Multiple crystal structures and evaluations of the ligand promiscuity of CYP3A4 have been reported, resulting in a prominent role for the enzyme in the biotransformation of xenobiotics and endogenous compounds (Ekroos and Sjogren, 2006; Foti et al., 2011; Foti et al., 2010; Gibbs and Hosea, 2003; Kenworthy et al., 1999; Wienkers and Heath, 2005; Williams et al., 2004; Yano et al., 2004) . Binding within the active site of CYP3A4 has also been shown to be related to lipophilicity and conformational changes to the active site of CYP3A4 upon ligand binding have been reported (Ishigami et al., 2001; Kenworthy et al., 2001; Khan et al., 2002; Korzekwa et al., 1998; Lu et al., 2001; Riley et al., 2001; Shou et al., 1994) . Interactions between astemizole and the phenylalanine cluster of CYP3A4 were observed, with Phe215, Domanski et al., 1998; He et al., 1997; Khan and Halpert, 2000; Tanaka et al., 2004) . The three binding models for astemizole with CYP3A4 also predict significant interactions with a polar region of the active site which includes Arg106 and Glu374, a region known to be involved in the binding of ketoconazole as well as with Arg212, which is known to undergo significant conformational changes between the ligand-free and ligand-bound structures of CYP3A4 (Ekroos and Sjogren, 2006; Sevrioukova and Poulos, 2012; Yano et al., 2004 
